Selpercatinib: First Approval
Anthony Markham
Abstract
Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. This article summarizes the milestones in the development of selpercatinib leading to this first approval.
Topics & Concepts
MedicineMedullary thyroid cancerVandetanibThyroid cancerOncologyLung cancerTyrosine-kinase inhibitorInternal medicineCancerTargeted therapyTyrosine kinaseCancer researchReceptorLung Cancer Treatments and MutationsThyroid Cancer Diagnosis and TreatmentLung Cancer Diagnosis and Treatment